GlassScriptPhysician profile
Mark S Tuttle
NPI 1821029562
$95,158.52
in general payments reported to CMS, 2019-2025
18 companies · $979 in 2025
The $979 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
See the full distribution for Adult Reconstructive Orthopaedic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $9,353 · 2021: $53K · 2022: $20K · 2023: $4,819 · 2024: $5,728 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $1,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,263.95 |
| Food and Beverage | $1,262.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uoc USA INC | $91,585.17 | 2019-2025 | U2 Press-Fit, Ustar II, U2 Pf+ |
| Molnlycke Health Care US, LLC | $1,608.83 | 2019-2022 | |
| Abbott Laboratories | $631.05 | 2021-2025 | Mitraclip, Cardiomems, Amplatzer Amulet |
| Depuy Synthes Sales INC. | $233.53 | 2019-2020 | |
| Stryker Corporation | $182.84 | 2019-2021 | |
| Shockwave Medical, INC | $160.11 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Smith+Nephew, INC. | $144.26 | 2019-2021 | |
| Illuminoss Medical, INC. | $139.04 | 2020-2025 | |
| Zimmer Biomet Holdings, INC. | $120.53 | 2019 | |
| Pacira Therapeutics, INC. | $96.63 | 2020-2021 | |
| Wound Management Technologies, INC | $85.87 | 2019 | |
| Kuros Biosciences USA, INC | $42.24 | 2023 | |
| Cardiovascular Systems INC. | $39.93 | 2021 | |
| Next Science LLC | $33.05 | 2022 | |
| Acell, INC. | $21.60 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.24 | 2021 | |
| Theragen, INC. | $13.60 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$440,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.